← Back to Search

[18F]FLOR PET/CT Imaging for Prostate Cancer

Phase 1
Waitlist Available
Led By Steven Rowe, M.D., Ph.D.
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 days post-study drug dosing
Awards & highlights

Study Summary

This trial is testing how well a new imaging technique can detect prostate cancer that has spread to other parts of the body.

Who is the study for?
This trial is for men over 18 with confirmed adenocarcinoma of the prostate who have signs of recurring or spreading cancer. They must not have had cancer treatment in the last 2 weeks and should be able to follow study procedures. Men who've recently received radioisotopes or have conditions that may skew results can't participate.Check my eligibility
What is being tested?
[18F]FLOR (FC303) PET/CT imaging is being tested for its safety and ability to detect metastatic prostate cancer. Participants will receive an injection of [18F]FLOR, followed by a PET/CT scan to identify if their cancer has spread.See study design
What are the potential side effects?
While specific side effects are not listed, participants will be monitored for any adverse reactions following the injection of [18F]FLOR (FC303), which could range from mild allergic reactions to more serious complications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 days post-study drug dosing
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 days post-study drug dosing for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of study drug emergent adverse events

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]FLOR (FC303)Experimental Treatment1 Intervention
[18F]FLOR (FC303) PET/CT imaging.

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
561 Previous Clinical Trials
33,091 Total Patients Enrolled
58 Trials studying Prostate Cancer
3,428 Patients Enrolled for Prostate Cancer
FutureChemIndustry Sponsor
5 Previous Clinical Trials
563 Total Patients Enrolled
Steven Rowe, M.D., Ph.D.Principal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
23 Total Patients Enrolled
1 Trials studying Prostate Cancer
23 Patients Enrolled for Prostate Cancer

Media Library

[18F]FLOR (FC303) Injection Clinical Trial Eligibility Overview. Trial Name: NCT04528199 — Phase 1
Prostate Cancer Research Study Groups: [18F]FLOR (FC303)
Prostate Cancer Clinical Trial 2023: [18F]FLOR (FC303) Injection Highlights & Side Effects. Trial Name: NCT04528199 — Phase 1
[18F]FLOR (FC303) Injection 2023 Treatment Timeline for Medical Study. Trial Name: NCT04528199 — Phase 1
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top